Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed Papers

Quality of life outcomes with BG-12 (dimethyl fumarate) in patients with relapsing-remitting multiple sclerosis: The DEFINE study.
Multiple sclerosis in pregnancy.
Daclizumab phase II trial in relapsing and remitting multiple sclerosis: MRI and clinical results.
Clinical and MRI predictors of response to interferon-beta and glatiramer acetate in relapsing-remitting multiple sclerosis patients.
Allelic combinations of immune-response genes associated with glatiramer acetate treatment response in Russian multiple sclerosis patients.
Oligodendrogenesis and myelinogenesis during postnatal development effect of glatiramer acetate.
Effects of fumaric acid esters on blood-brain barrier tight junction proteins.
Genzyme provides update on U.S. LEMTRADA™ filing
Autoimmune AQP4 channelopathies and neuromyelitis optica spectrum disorders.
The Charcot Lecture | Beating MS: A story of B cells, with twists and turns.
An update on the evidence for the efficacy and safety of rituximab in the management of neuromyelitis optica.
A benefit-risk analysis of natalizumab in the treatment of patients with multiple sclerosis when considering the risk of progressive multifocal leukoencephalopathy.
Benzothiazole and stilbene derivatives as promising PET myelin radiotracers for multiple sclerosis.
Clinical efficacy assessment in photodamaged skin of 0.5% and 1.0% idebenone.
Estrogen treatment in multiple sclerosis.
Prediction of oxygen uptake during walking in ambulatory persons with multiple sclerosis.
Use of interleukin-2 for management of natalizumab-associated progressive multifocal leukoencephalopathy: case report and review of literature.
Interferon-beta(1b) treatment in neuromyelitis optica.
Placebo-controlled multicentre randomised trial of interferon beta-1b in treatment of secondary progressive multiple sclerosis. European Study Group on interferon beta-1b in secondary progressive MS.
Secretory products of multiple sclerosis B cells are cytotoxic to oligodendroglia in vitro.
Treatment satisfaction in multiple sclerosis.
Genzyme reports positive top-line results of TOWER, a pivotal phase III trial for AUBAGIO(TM*) (teriflunomide) in relapsing multiple sclerosis
Long-term effect of early treatment with interferon beta-1b after a first clinical event suggestive of multiple sclerosis: 5-year active treatment extension of the phase 3 BENEFIT trial.
Primary infection with the Epstein-Barr virus and risk of multiple sclerosis.
Glatiramer acetate (GA) prevents TNF-α-induced monocyte adhesion to primary endothelial cells through interfering with the NF-κB pathway.

Pages